Treatment with 9-cis β-carotene-rich powder in patients with retinitis pigmentosa a randomized crossover trial

JAMA Ophthalmology

Volumn 131, Issue 8, 2013, Pages 985-992

  Rotenstreich, Ygal ^a,c   Belkin, Michael ^a   Sadetzki, Siegal ^a,b   Chetrit, Angela ^b   Ferman Attar, Gili ^a   Sher, Ifat ^a   Harari, Ayelet ^c   Shaish, Aviv ^c   Harats, Dror ^a,c  

^a TEL AVIV UNIVERSITY   (Israel)

^b GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

9 CIS BETA CAROTENE; BETA CAROTENE; PLACEBO; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; B WAVE; BEST CORRECTED VISUAL ACUITY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DARK ADAPTATION; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; DUNALIELLA BARDAWIL; FEMALE; HUMAN; LIGHT ADAPTATION; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINITIS PIGMENTOSA; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ACUITY; VISUAL FIELD;

ADMINISTRATION, ORAL; ADULT; AGED; BETA CAROTENE; CHLOROPHYTA; CROSS-OVER STUDIES; DARK ADAPTATION; DOUBLE-BLIND METHOD; ELECTRORETINOGRAPHY; FEMALE; HUMANS; LIGHT; MALE; MIDDLE AGED; POWDERS; RETINA; RETINITIS PIGMENTOSA; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL FIELDS; VITAMINS; YOUNG ADULT;

EID: 84881622388     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2013.147     Document Type: Article

References (35)

1. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006;368(9549):1795-1809.
2. Travis GH, Golczak M, Moise AR, Palczewski K. Diseases caused by defects in the visual cycle: Retinoids as potential therapeutic agents. Annu Rev Pharmacol Toxicol. 2007;47:469-512.
3. Fan J, Rohrer B, Moiseyev G,Ma JX, Crouch RK. Isorhodopsin rather than rhodopsin mediates rod function in RPE65 knock-out mice. Proc Natl Acad Sci U S A. 2003;100(23):13662-13667.
4. Van Hooser JP, Liang Y, Maeda T, et al. Recovery of visual functions in a mouse model of Leber congenital amaurosis. J Biol Chem. 2002;277(21): 19173-19182.
5. Van Hooser JP, Aleman TS, He YG, et al. Rapid restoration of visual pigment and function with oral retinoid in a mouse model of childhood blindness. Proc Natl Acad Sci U S A. 2000;97(15):8623-8628.
6. Maeda A, Maeda T, Palczewski K. Improvement in rod and cone function in mouse model of fundus albipunctatus after pharmacologic treatment with 9-cis-retinal. Invest Ophthalmol Vis Sci. 2006;47(10):4540-4546.
7. Gearhart PM, Gearhart C, Thompson DA, Petersen-Jones SM. Improvement of visual performance with intravitreal administration of 9-cis-retinal in Rpe65-mutant dogs. Arch Ophthalmol. 2010;128(11):1442-1448.
8. Ablonczy Z, Crouch RK, Goletz PW, et al. 11-cis-Retinal reduces constitutive opsin phosphorylation and improves quantum catch in retinoid-deficient mouse rod photoreceptors. J Biol Chem. 2002;277(43):40491- 40498.
9. Gao SQ, Maeda T, Okano K, Palczewski K. A microparticle/hydrogel combination drug-delivery system for sustained release of retinoids. Invest Ophthalmol Vis Sci. 2012;53(10):6314-6323. doi:10.1167/iovs.12-10279.
10. Koenekoop R, Racine J, Al Humaid S, et al. Oral synthetic cis-retinoid therapy in subjects with Leber congenital amaurosis (LCA) due to lecithin: Retinol acyltransferase (LRAT) or retinal pigment epithelial 65 protein (RPE65) mutations: Preliminary results of a phase Ib open-label trial [ARVO abstract]. http://www.abstractsonline.com/Plan/ViewAbstract .aspx?sKey=9456c86d-1d58-492c- ab4f-bc1dfbebebee&cKey=c1849603-6a33-4902-b43d-cdcc29d30c6d&mKey= {6F224A2D-AF6A-4533-8BBB-6A8D7B26EDB3}. Accessed May 22, 2012.
11. Rotenstreich Y, Harats D, Shaish A, Pras E, Belkin M. Treatment of a retinal dystrophy, fundus albipunctatus, with oral 9-cis-β-carotene. Br J Ophthalmol. 2010;94(5):616-621.
12. Ben-Amotz A, Lers A, Avron M. Stereoisomers of β-carotene and phytoene in the alga Dunaliella bardawil. Plant Physiol. 1988;86(4):1286-1291.
13. Omenn GS, Goodman GE, Thornquist MD, et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst. 1996;88(21): 1550-1559.
14. Lippman SM, Lee JJ, Karp DD, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst. 2001;93(8):605-618.
15. Goralczyk R. Beta-carotene and lung cancer in smokers: Review of hypotheses and status of research. Nutr Cancer. 2009;61(6):767-774.
16. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996;334(18):1145-1149.
17. Kamangar F, Qiao YL, Yu B, et al. Lung cancer chemoprevention: A randomized, double-blind trial in Linxian, China. Cancer Epidemiol Biomarkers Prev. 2006;15(8):1562-1564.
18. Shaish A, Harari A, Hananshvili L, et al. 9-cis β-Carotene-rich powder of the alga Dunaliella bardawil increases plasma HDL-cholesterol in fibrate-treated patients. Atherosclerosis. 2006;189(1):215-221.
19. Greenberger S, Harats D, Salameh F, et al. 9-cis-Rich β-carotene powder of the alga Dunaliella reduces the severity of chronic plaque psoriasis: A randomized, double-blind, placebo-controlled clinical trial. J AmColl Nutr. 2012;31(5):320-326.
20. Marmor MF, Fulton AB, Holder GE,Miyake Y, BrigellM, Bach M; International Society for Clinical Electrophysiology of Vision. ISCEV standard for full-field clinical electroretinography (2008 update). Doc Ophthalmol. 2009;118(1):69-77.
21. Rotenstreich Y, Fishman GA, Lindeman M, Alexander KR. The application of chromatic dark-adapted kinetic perimetry to retinal diseases. Ophthalmology. 2004;111(6):1222-1227.
22. Harari A, Harats D, Marko D, et al. A 9-cis β-carotene-enriched diet inhibits atherogenesis and fatty liver formation in LDL receptor knockout mice. J Nutr. 2008;138(10):1923-1930.
23. Maeda T, Perusek L, Amengual J, Babino D, Palczewski K, von Lintig J. Dietary 9-cis-β,β-carotene fails to rescue vision in mouse models of Leber congenital amaurosis. Mol Pharmacol. 2011;80(5):943-952.
24. Wang XD, Krinsky NI, Benotti PN, Russell RM. Biosynthesis of 9-cis-retinoic acid from 9-cis-beta-carotene in human intestinal mucosa in vitro. Arch Biochem Biophys. 1994;313(1):150-155.
25. StahlW, SchwarzW, Sundquist AR, Sies H. cis-trans Isomers of lycopene and beta-carotene in human serum and tissues. Arch Biochem Biophys. 1992;294(1):173-177.
26. Huterne X,Wang XD, Johnson EJ, Krinsky NI, Russell RM. Intestinal absorption and metabolism of 9-cis-beta-carotene in vivo: Biosynthesis of 9-cis-retinoic acid. J Lipid Res. 1995;36(6): 1264-1273.
27. Maeda T, Maeda A, Casadesus G, Palczewski K, Margaron P. Evaluation of 9-cis-retinyl acetate therapy in Rpe65/mice. Invest Ophthalmol Vis Sci. 2009;50(9):4368-4378.
28. Rohrer B, Lohr HR, Humphries P, Redmond TM, SeeligerMW, Crouch RK. Cone opsinmislocalization in Rpe65/mice: A defect that can be corrected by 11-cis retinal. Invest Ophthalmol Vis Sci. 2005;46(10):3876-3882.
29. Heyman RA, Mangelsdorf DJ, Dyck JA, et al. 9-cis Retinoic acid is a high affinity ligand for the retinoid X receptor. Cell. 1992;68(2):397-406.
30. Esfahani A,Wong JM, Truan J, et al. Health effects ofmixed fruit and vegetable concentrates: A systematic review of the clinical interventions. J Am Coll Nutr. 2011;30(5):285-294.
31. Paiva SA, Russell RM. β-Carotene and other carotenoids as antioxidants. J AmColl Nutr. 1999;18(5):426-433.
32. Giordano P, Scicchitano P, Locorotondo M, et al. Carotenoids and cardiovascular risk. Curr Pharm Des. 2012;18(34):5577-5589.
33. Busskamp V, Duebel J, Balya D, et al. Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa. Science. 2010;329(5990):413-417.
34. Lin B, Masland RH, Strettoi E. Remodeling of cone photoreceptor cells after rod degeneration in rd mice. Exp Eye Res. 2009;88(3):589-599.
35. Radu RA, Han Y, Bui TV, et al. Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: A potential therapy for treatment of lipofuscin-based retinal diseases. Invest Ophthalmol Vis Sci. 2005;46(12):4393-4401.